Month: October 2026

CARMEL, Ind., Oct. 27, 2026 (GLOBE NEWSWIRE) — NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report summarized financial results for its third quarter period ended September 30, 2026, on Monday, November 9, 2026, before market open. The Company has scheduled a conference call for the same day, Monday, November 9, 2026, at 9:00 am ET to review the results.

Conference Call Details

Date and Time: Monday, November 9, 2026, at 9:00am ET

Toll Free: 1-833-862-0272 (U.S. and Canada toll-free) International: 1-412-634-5915
Webcast: https://app.webinar.net/B2bPr8Dro8e

Replay: Toll Free: 1-855-669-9658 (U.S. and Canada toll-free) International: 1-412-317-0088
Replay access code: 9067695
Webcast: https://app.webinar.net/B2bPr8Dro8e

About NeurAxis, Inc.
NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of IB-Stim® , which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is FDA cleared for functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD), and FD-related nausea symptoms in patients 8 years and older. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway.

For more information, please visit http://neuraxis.com.

Investor Relations
Lytham Partners
Ben Shamsian
646-829-9701
shamsian@lythampartners.com

• Third quarter revenue of $209 million, a year-over-year increase of 11% as reported and 12.5% organic
• Closed BioLife acquisition, which fast-tracks Repligen’s leadership and offering in high-growth cell therapy market
• Raising FY26 revenue guidance to $844-$852 million which represents reported revenue growth of 14.5% – 15.5%

WALTHAM, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN), today reported financial results for its third quarter of 2026, covering the three-month period ended September 30, 2026. The Company is also providing updated financial guidance for the full year 2026.

Olivier Loeillot, President and Chief Executive Officer of Repligen said, “We delivered a record third quarter, with $209 million in revenue and 12.5% organic growth, driven by continued strength across our diversified portfolio. End-market demand continues to improve, with healthy trends in consumables and services complemented by a growing capital equipment order book.”

Mr. Loeillot continued, “The completion of the BioLife acquisition in October marks a significant milestone for Repligen, and integration is progressing well. Early customer feedback has been very encouraging, and we have already taken actions to realize a sizable portion of our expected operating expense synergies. Our strong year-to-date performance, continued order momentum and the addition of BioLife give us confidence to raise our full-year guidance again.”

BUSINESS HIGHLIGHTS

• Completed Acquisition of BioLife Solutions. The acquisition strengthens Repligen’s position in cell therapy by adding a differentiated, deeply embedded consumables platform with recurring revenue, commercial-stage exposure, and strong customer workflow integration. The combination expands Repligen’s portfolio and is expected to enhance the Company’s long-term growth, margin profile, and earnings power.
• New Repligen Training & Innovation Center (“RTIC”). On October 23, 2026, opened a new RTIC in Seoul, South Korea. This underscores Repligen’s commitment to a strategically important market that has become one of the world’s leading hubs for biologics and CDMO manufacturing.

FINANCIAL PERFORMANCE

Q3 2026 Financial Performance (compared to prior year periods except as noted)

All adjusted figures are non-GAAP and, except for earnings per share (“EPS”), are rounded to the nearest million, and are reconciled in the tables included later in this press release.

• Q3 reported revenue was $209.3 million, compared to $188.8 million, an increase of 11% as reported and 12.5% organic.
• GAAP Results. Q3 loss from operations was $29.5 million primarily driven by intangible asset impairment charge, compared to income from operations of $16.8 million. Q3 loss per share was $0.68 on a fully diluted basis, compared to EPS of $0.26.
• Adjusted Results. Q3 adjusted income from operations was $33.3 million, compared to $26.8 million. Q3 adjusted EPS was $0.53 on a fully diluted basis, compared to $0.46.

MARGIN SUMMARY

GAAP Margins		Q3 2026			Q3 2025			Q3-YTD 2026			Q3-YTD 2025
Gross Margin		53.0	%		53.2	%		54.2	%		52.7	%
Operating (Loss) EBIT Margin		(14.1	)%		8.9	%		0.1	%		6.9	%
Net (Loss) Income Margin		(18.4	)%		7.9	%		(4.1	)%		6.6	%
Adjusted (non-GAAP) Margins		Q3 2026			Q3 2025			Q3-YTD 2026			Q3-YTD 2025
Gross Margin		53.0	%		53.3	%		54.1	%		52.7	%
Operating (EBIT) Margin		15.9	%		14.2	%		16.0	%		13.3	%
Net Income Margin		14.3	%		13.7	%		14.4	%		12.8	%
EBITDA Margin		20.9	%		19.0	%		21.0	%		18.7	%

Cash, cash equivalents and marketable securities at September 30, 2026, were $863 million, compared to $768 million at December 31, 2025.

FINANCIAL GUIDANCE FOR FULL YEAR 2026

All adjusted figures are non-GAAP.

Our financial guidance for the full year 2026 includes the expected impact of BioLife Solutions from the closing date of October 6, 2026. Our Adjusted (non-GAAP) guidance excludes the impact of any other potential business acquisitions and future fluctuations in foreign currency exchange rates.

	CURRENT GUIDANCE
	(at October 27, 2026)
FY 2026	Adjusted (non-GAAP)
Total Reported Revenue	$844M – $852M
Reported Growth	14.5% – 15.5%
Organic Growth	12% – 13%
Gross Margin	53.7% – 54.2%
Income from Operations	$135M – $139M
Operating Margin	16.0% – 16.3%
Other Income (Expense)	~$18M
Adjusted EBITDA Margin	~21%
Tax Rate on Pre-Tax Income	~22%
Net Income	$119M – $122M
Earnings Per Share – Diluted	$2.05 – $2.09

Total reported revenue guidance reflects a neutral impact from foreign currency and an approximately 2.5 point tailwind from inorganic growth primarily from the BioLife acquisition net of the divestiture of Polymem.

Conference Call and Webcast Access

Repligen will host a conference call and webcast today, October 27, 2026, at 8:00 a.m. ET, to discuss third quarter 2026 financial results, corporate developments and financial guidance for 2026. The conference call will be accessible by dialing toll-free (833) 461-5787 for domestic callers and (585) 542-9983 for international callers. The meeting ID is: 877042431. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. The webcast will be archived for a period of time following the live event. You can access the replay on the Investor Relations section of the Company’s website.

About Repligen Corporation

Repligen Corporation is a global bioprocessing company that develops and commercializes innovative technologies and integrated solutions that support critical steps in the manufacturing and delivery of biologic drugs that improve human health worldwide. As a trusted partner to biopharmaceutical developers and manufacturers and CDMOs worldwide, we help improve productivity, simplify complex workflows, and advance the next generation of biologic therapies. Repligen technologies support the production of a broad range of biologic modalities, helping customers navigate evolving manufacturing challenges from process development through commercial production. Our global team combines deep scientific expertise, innovation, and a customer-focused mindset “inspiring advances in bioprocessing” to help solve complex challenges across biologics manufacturing. For more information, please visit our website at https://www.repligen.com/, and follow us on LinkedIn.

Non-GAAP Measures of Financial Performance

To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (“GAAP”), the following Adjusted (“non-GAAP”) measures of financial performance are included in this release: organic revenue and organic revenue growth; adjusted gross profit and adjusted gross margin; adjusted income from operations and adjusted operating margin; organic adjusted operating margin year-over-year change; adjusted net income and adjusted net income margin; adjusted earnings per share (diluted); adjusted earnings before interest, taxes, depreciation and amortization (EBITDA), and adjusted EBITDA margin. The Company provides the impact of foreign currency translation, to enable determination of revenue and margin growth rates at constant currency. To calculate the impact of foreign currency translation, the Company converts the reported amounts from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior year periods.

The Company’s non-GAAP financial results and/or non-GAAP guidance exclude the impact of: acquisition, integration and divestiture costs; restructuring charges including the costs of severance and accelerated depreciation among other non-cash charges; inventory step-up costs and adjustments; transformation costs including incremental, non-recurring expenses for discrete strategic projects that are designed to deliver long-term benefits, including improvements to enhance productivity and enable company growth that do not meet the definition of restructuring; contingent consideration related to the Company’s acquisitions; intangible amortization costs; intangible asset impairment charges; non-cash interest expense related to the accretion of the debt discount; amortization of debt issuance costs related to Company’s convertible debt; foreign currency impact of certain intercompany loans; loss on sale of business; and, the related impact on tax of non-GAAP charges.

These costs are excluded because management believes that such expenses do not have a direct correlation to future business operations, nor do the resulting charges recorded accurately reflect the performance of our ongoing operations for the period in which such charges are recorded. Additionally, for a project to be considered transformational, the project expenses are expected to bring long-term growth, profitability improvements and defined process and technology improvements. Our transformation initiative is multi-year but each project has a discrete, defined timeline. Further, organic adjusted operating margin year-over-year change excludes the effect of adjustments above, as well as the impact of mergers, acquisitions and divestitures and foreign exchange. This measure is used by the Company in periods of acquisition because the timing, size and number of such transactions and their related impact on the financial statements may vary and make comparison of long-term results difficult.

All reconciliations of above GAAP figures to adjusted (non-GAAP) figures are detailed in the tables included later in this press release. Certain prior year amounts have been reclassified to conform with the current year presentation. When analyzing the Company’s operating performance and guidance, investors should not consider non-GAAP measures as a substitute for the comparable financial measures prepared in accordance with GAAP.

The Company does not provide GAAP financial measures on a forward-looking basis as the Company is unable to provide a quantitative reconciliation of forward-looking non-GAAP measures to the most directly comparable forward-looking GAAP measure, without unreasonable effort. The Company cannot reasonably predict items including, but not limited to, the timing and amount of future restructuring and cost-savings actions or transformation, acquisition and integration related costs. These items are generally uncertain and are not indicative of ongoing operations of the business, and the impact could be material to our results in accordance with GAAP.

Forward-Looking Statements

This press release contains forward-looking statements, which are made pursuant to and in reliance upon the safe harbor provisions of federal securities laws, including the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained herein which do not describe historical facts, including, among others, any express or implied statements or guidance regarding current or future financial performance and position, including our 2026 financial guidance and related assumptions; expected demand in the markets in which we operate; and the expected performance of our business and momentum across our portfolio, are based on management’s current expectations and beliefs and are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements.

Such risks and uncertainties include, among others, our ability to successfully grow our bioprocessing business; our ability to manage through and predict headwinds; the risk that we have assumed that markets and franchises will improve and grow as predicted; our ability to achieve our 2026 financial guidance; our ability to develop and commercialize products and the market acceptance of our products; our ability to successfully integrate BioLife, including its operations, products, systems and personnel, in a timely manner or at all, and to realize the expected benefits and synergies of the acquisition; the future performance of BioLife and the combined company, including the impact of the acquisition on our financial results and outlook; the risk of unanticipated costs, liabilities or disruptions to our or BioLife’s business, customer, supplier or employee relationships resulting from the acquisition; our ability to successfully integrate any other acquired businesses and relevant personnel in a timely manner or at all, and to achieve the expected benefits of such acquisitions; the risk that demand for our products could decline, which could adversely impact our future revenues, cash flows, results of operations and financial condition; our ability to compete with larger, better financed bioprocessing companies; risks around the Company’s effectiveness of disclosure controls and procedures and the effectiveness of our internal control over financial reporting; our compliance with all U.S. Food and Drug Administration and European Medicines Evaluation Agency regulations; our volatile stock price; the impact of tariffs on our business, and other risks and uncertainties detailed in Repligen’s filings with the U.S. Securities and Exchange Commission (the Commission), including our Annual Report on Form 10-K for the year ended December 31, 2025 and in subsequently filed reports with the Commission, including our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and any subsequent filings made with the Commission, which are available at the Commission’s website at www.sec.gov. Actual results may differ materially from those Repligen contemplated by these forward-looking statements, which reflect management’s current views, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions, and are based only on information currently available to us. Repligen cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Repligen disclaims any obligation to update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Repligen Contact:
Jacob Johnson
VP, Investor Relations
(781) 419-0204
investors@repligen.com

REPLIGEN CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited, amounts in thousands, except share data)

	September 30, 2026				December 31, 2025
ASSETS
Current assets:
Cash and cash equivalents	$	726,960			$	566,021
Marketable securities		136,019				201,607
Accounts receivable, net of allowances of $3,273 and $2,767 at September 30, 2026, and December 31, 2025, respectively		151,235				158,587
Inventories, net		182,205				170,458
Prepaid expenses and other current assets		45,565				40,712
Total current assets		1,241,984				1,137,385
Property, plant and equipment, net		163,561				186,614
Intangible assets, net		305,291				386,147
Goodwill		1,100,319				1,114,408
Deferred tax assets		716				694
Operating lease right of use assets		112,472				119,538
Other noncurrent assets		2,065				4,913
Total assets	$	2,926,408			$	2,949,699
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	27,697			$	30,010
Operating lease liabilities		20,397				21,559
Contingent consideration		2,254				5,049
Accrued liabilities		75,338				79,208
Total current liabilities		125,686				135,826
Convertible Senior Notes due 2028, net		555,596				542,213
Deferred tax liabilities		19,909				22,496
Noncurrent operating lease liabilities		116,248				126,176
Noncurrent contingent consideration		—				1,304
Other noncurrent liabilities		17,232				15,555
Total liabilities		834,671				843,570
Stockholders’ equity:
Preferred stock, $0.01 par value, 5,000,000 shares authorized, no shares issued or outstanding		—				—
Common stock, $0.01 par value; 80,000,000 shares authorized; 56,692,755 shares at September 30, 2026, and 56,325,429 shares at December 31, 2025, issued and outstanding		567				563
Additional paid-in capital		1,685,620				1,651,849
Accumulated other comprehensive loss		(25,607	)			(2,531	)
Retained earnings		431,157				456,248
Total stockholders’ equity		2,091,737				2,106,129
Total liabilities and stockholders’ equity	$	2,926,408			$	2,949,699

REPLIGEN CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited, amounts in thousands, except per share data)

	Three Months Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
Revenue:
Product	$	209,270			$	188,766			$	607,566			$	540,232
Royalty and other revenue		44				39				131				111
Total revenue		209,314				188,805				607,697				540,343
Costs and operating expenses:
Cost of goods sold		98,328				88,290				278,390				255,462
Research and development		14,435				14,175				43,310				40,259
Selling, general and administrative		83,592				73,663				236,746				215,275
Restructuring activities and other charges		1,966				—				6,180				4,135
Intangible asset impairment charges		41,242				—				41,242				—
Change in fair value of contingent consideration		(703	)			(4,148	)			1,459				(12,087	)
Total costs and operating expenses		238,860				171,980				607,327				503,044
(Loss) income from operations		(29,546	)			16,825				370				37,299
Other income (expense), net:
Investment income		7,000				6,921				19,773				20,820
Interest expense		(5,712	)			(5,414	)			(16,953	)			(16,018	)
Amortization of debt issuance costs		(422	)			(416	)			(1,262	)			(1,243	)
Loss on sale of business		(34	)			—				(13,694	)			—
Other income (expense), net		1,906				(804	)			883				2,412
Other income (expense), net		2,738				287				(11,253	)			5,971
(Loss) income before income taxes		(26,808	)			17,112				(10,883	)			43,270
Income tax provision		11,624				2,201				14,208				7,663
Net (loss) income	$	(38,432	)		$	14,911			$	(25,091	)		$	35,607
(Loss) earnings per share:
Basic	$	(0.68	)		$	0.27			$	(0.44	)		$	0.63
Diluted	$	(0.68	)		$	0.26			$	(0.44	)		$	0.63
Weighted average common shares outstanding:
Basic		56,558				56,265				56,445				56,208
Diluted		56,558				56,532				56,445				56,520

REPLIGEN CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited, amounts in thousands)

	Nine Months Ended September 30,
		2026				2025
Cash flows from operating activities
Net (loss) income	$	(25,091	)		$	35,607
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization		57,948				58,794
Intangible asset impairment charges		41,242				—
Amortization of debt discount and issuance costs		13,383				12,360
Inventory step-up amortization		—				1,069
Loss on sale of business		13,694				—
Stock-based compensation		25,690				24,621
Deferred income taxes, net		(944	)			(5,784	)
Change in fair value of contingent consideration		1,459				(12,087	)
Net unrealized foreign exchange loss (gain)		(683	)			(12,443	)
Operating lease right of use asset amortization		14,189				13,570
Other adjustments and non-cash items		(1,754	)			2,532
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable		3,383				(7,302	)
Inventories		(16,070	)			(5,346	)
Prepaid expenses and other current assets		(3,732	)			(5,494	)
Other noncurrent assets		1,916				(1,727	)
Accounts payable		(523	)			(5,083	)
Accrued liabilities		(2,443	)			9,629
Operating lease liabilities		(18,796	)			(12,096	)
Noncurrent liabilities		1,292				893
Total cash provided by operating activities		104,160				91,713
Cash flows from (for) investing activities
Acquisitions, net of cash acquired		—				(69,954	)
Divestiture proceeds, net of cash divested		3,637				—
Purchases of marketable securities		(200,499	)			—
Maturities and sales of marketable securities		271,073				—
Additions to capitalized software costs		(1,307	)			(2,055	)
Purchases of property, plant and equipment		(14,992	)			(15,366	)
Sale of property, plant and equipment		—				42
Other investing activities		—				(2,397	)
Total cash provided by (used in) investing activities		57,912				(89,730	)
Cash flows from (for) financing activities
Proceeds from exercise of stock options		15,850				2,142
Payment of tax withholding obligation on vesting of restricted stock		(7,765	)			(7,994	)
Payment of earnout consideration		(5,225	)			(9,548	)
Total cash provided by (used in) financing activities		2,860				(15,400	)
Effect of exchange rate changes on cash, cash equivalents and restricted cash		(1,943	)			4,809
Net increase (decrease) in cash, cash equivalents and restricted cash		162,989				(8,608	)
Cash, cash equivalents and restricted cash, beginning of period	$	566,021			$	757,355
Cash, cash equivalents and restricted cash, end of period	$	729,010			$	748,747

RECONCILIATIONS OF GAAP TO NON-GAAP FINANCIAL MEASURES

(Unaudited, amounts in thousands, except percentage and earnings per share data)
In all tables below, totals may not add due to rounding

Reconciliation of Total Revenue (GAAP) Growth to Organic Revenue Growth (Non-GAAP)

	Three Months Ended September 30,						Nine Months Ended September 30,
	2026			2025			2026			2025
TOTAL REPORTED REVENUE (GAAP) GROWTH	11	%		22	%		13	%		16	%
Acquisition and divestiture revenue	1	%		(2	)%		0	%		(1	)%
Currency exchange	1	%		(2	)%		(1	)%		(1	)%
ORGANIC REVENUE GROWTH (NON-GAAP)	12	%		18	%		12	%		14	%

Reconciliation of (Loss) Income from Operations (GAAP) to Adjusted Income from Operations (Non-GAAP)

	Three Months Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
(LOSS) INCOME FROM OPERATIONS (GAAP)	$	(29,546	)		$	16,825			$	370			$	37,299
ADJUSTMENTS TO (LOSS) INCOME FROM OPERATIONS (GAAP):
Acquisition, integration and divestiture costs		8,078				4,406				12,896				14,721
Restructuring activities and other charges (1)		1,966				186				6,180				4,357
Transformation costs (2)		3,271				(975	)			6,349				(3,268	)
Intangible amortization		9,561				9,963				28,902				29,288
Intangible asset impairment charges		41,242				—				41,242				—
Contingent consideration		(703	)			(4,148	)			1,459				(12,087	)
Inventory step-up charges		—				492				—				1,069
Other (3)		(581	)			21				(202	)			707
ADJUSTED INCOME FROM OPERATIONS (NON-GAAP)	$	33,288			$	26,770			$	97,196			$	72,086
OPERATING (LOSS) EBIT MARGIN (GAAP)		(14.1	)%			8.9	%			0.1	%			6.9	%
ADJUSTED OPERATING (EBIT) MARGIN (NON-GAAP)		15.9	%			14.2	%			16.0	%			13.3	%

Reconciliation of Net (Loss) Income (GAAP) to Adjusted Net Income (Non-GAAP)

	Three Months Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
NET (LOSS) INCOME (GAAP)	$	(38,432	)		$	14,911			$	(25,091	)		$	35,607
ADJUSTMENTS TO NET (LOSS) INCOME (GAAP):
Acquisition, integration and divestiture costs		8,078				4,406				12,896				14,721
Restructuring activities and other charges (1)		1,966				186				6,180				4,357
Transformation costs (2)		3,271				(975	)			6,349				(3,268	)
Intangible amortization		9,561				9,963				28,902				29,288
Intangible asset impairment charges		41,242				—				41,242				—
Contingent consideration		(618	)			(4,232	)			1,446				(15,285	)
Inventory step-up charges		—				492				—				1,069
Non-cash interest expense		4,209				3,907				12,444				11,481
Amortization of debt issuance costs		422				416				1,262				1,243
Foreign currency impact of certain intercompany loans (3)		(1,004	)			—				504				—
Loss on sale of business		34				—				13,694				—
Other (4)		(581	)			21				(202	)			707
Tax effect of non-GAAP charges		1,732				(3,233	)			(11,815	)			(10,662	)
ADJUSTED NET INCOME (NON-GAAP)	$	29,880			$	25,862			$	87,811			$	69,258
NET (LOSS) INCOME MARGIN (GAAP)		(18.4	)%			7.9	%			(4.1	)%			6.6	%
ADJUSTED NET INCOME MARGIN (NON-GAAP)		14.3	%			13.7	%			14.4	%			12.8	%

Reconciliation of Loss Per Share (GAAP) to EPS (Non-GAAP)

	Three Months Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
(LOSS) EPS (GAAP) – DILUTED	$	(0.68	)		$	0.26			$	(0.44	)		$	0.63
ADJUSTMENTS TO (LOSS) EPS (GAAP) – DILUTED:
Acquisition, integration and divestiture costs		0.14				0.08				0.23				0.26
Restructuring activities and other charges (1)		0.03				(0.01	)			0.11				0.02
Transformation costs (2)		0.06				0.00				0.11				0.00
Intangible amortization		0.17				0.18				0.51				0.52
Intangible asset impairment charges		0.72				—				0.73				—
Contingent consideration		(0.01	)			(0.07	)			0.03				(0.27	)
Inventory step-up charges		—				0.01				—				0.02
Non-cash interest expense		0.07				0.07				0.22				0.20
Amortization of debt issuance costs		0.01				0.01				0.02				0.02
Foreign currency impact of certain intercompany loans (3)		(0.02	)			—				0.01				—
Loss on sale of business		0.00				—				0.24				—
Other (4)		0.00				0.00				0.00				0.01
Tax effect of non-GAAP charges		0.03				(0.06	)			(0.21	)			(0.19	)
ADJUSTED EPS (NON-GAAP) – DILUTED (5)	$	0.53			$	0.46			$	1.55			$	1.23

Reconciliation of Net (Loss) Income (GAAP) to Adjusted EBITDA (Non-GAAP)

	Three Months Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
NET (LOSS) INCOME (GAAP)	$	(38,432	)		$	14,911			$	(25,091	)		$	35,607
ADJUSTMENTS:
Investment income		(7,000	)			(6,921	)			(19,773	)			(20,820	)
Interest expense		5,712				5,414				16,953				16,018
Amortization of debt issuance costs		422				416				1,262				1,243
Income tax (benefit) provision		11,624				2,201				14,208				7,663
Depreciation		9,563				10,101				29,046				29,506
Intangible amortization		9,561				9,908				28,902				29,288
(LOSS) EBITDA (NON-GAAP)	$	(8,550	)		$	36,030			$	45,507			$	98,505
OTHER ADJUSTMENTS:
Acquisition, integration and divestiture costs		8,078				4,406				12,896				14,721
Restructuring activities and other charges (1)		1,966				186				6,180				4,357
Transformation costs (2)		3,271				(975	)			6,349				(3,268	)
Intangible asset impairment charges		41,242				—				41,242				—
Contingent consideration		(618	)			(4,232	)			1,446				(15,285	)
Inventory step-up charges		—				492				—				1,069
Foreign currency impact of certain intercompany loans (3)		(1,004	)			—				504				—
Loss on sale of business		34				—				13,694				—
Other (4)		(581	)			21				(202	)			707
ADJUSTED EBITDA (NON-GAAP)	$	43,838			$	35,928			$	127,616			$	100,806
NET (LOSS) INCOME MARGIN (GAAP)		(18.4	)%			7.9	%			(4.1	)%			6.6	%
ADJUSTED EBITDA MARGIN (NON-GAAP)		20.9	%			19.0	%			21.0	%			18.7	%

FOOTNOTES FOR ALL TABLES ABOVE:
⁽¹⁾   Restructuring activities and other charges includes the costs of severance, lease impairment and accelerated depreciation among other non-cash charges. Charges for the three and nine months ended September 30, 2026, consists of activities to simplify the global manufacturing footprint of the organization and align its workforce to support long-term company growth.

⁽²⁾   For the three and nine months ended September 30, 2026, transformation costs include $3.9 million and $8.8 million, respectively, of expenses for discrete strategic projects that are designed to deliver long-term growth under our Transformation Office, partially offset by $0.6 million and $2.5 million, respectively, for the benefit received from the sale of inventory that had previously been reserved for as part of past restructuring plans. The three and nine months ended September 30, 2025, includes a benefit of $1.0 million and $3.3 million, respectively, from the sale of inventory that had previously been reserved as part of past restructuring plans.

⁽³⁾   During the three and nine months ended September 30, 2026, we recorded foreign currency (gains) and losses on certain intercompany loans of $(1.0) million and $0.5 million, respectively. This is recorded in other income (expense), net within the condensed consolidated statements of operations.

⁽⁴⁾   Other charges for the three and nine months ended September 30, 2026, includes other expenses or (benefits) that are non-indicative of our ongoing performance. The three and nine months ended September 30, 2025, includes charges related to one-time events relating to a cybersecurity incident, net of insurance, and costs associated with the restatement of previously issued financial statements.

⁽⁵⁾   GAAP loss per share—diluted for the three and nine months ended September 30, 2026, excludes 328,882 and 313,150 potentially dilutive shares, respectively, as their inclusion would have been antidilutive due to the net loss for each period. Adjusted earnings per share—diluted for the same periods was calculated using 56,886,642 and 56,757,704 diluted shares, respectively.

NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) — Marex Group Limited (‘Marex’ or the ‘Group’, NASDAQ: MRX), the diversified global financial services platform, today announces that Kory Sorenson will join the Group Board with effect from 2 November 2026.

Kory is a financial markets expert with more than 30 years of experience across governance, financial strategy and risk oversight at listed and privately owned organizations globally. She currently serves on the boards of a number of international companies spanning consumer goods, testing and inspection, financial services and private banking, where she has extensive experience chairing audit, risk and remuneration committees.

Prior to her non-executive career, Kory was Managing Director and Head of Insurance Capital Markets at Barclays Capital and Head of Insurance and French Bank Capital Markets at Credit Suisse. Throughout her executive career, she advised major European financial institutions on capital structuring, mergers and acquisitions, regulatory capital and risk management.

John Pietrowicz, Chair of the Marex Board, commented:
“We are delighted to welcome Kory to the Marex Board. She brings extensive experience across global financial markets, financial strategy and corporate governance, together with a strong track record of risk oversight and board leadership at major international organizations. We look forward to benefiting from her expertise and insight as Marex continues to grow.”

Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the expected benefits of Kory Sorenson’s appointment to the Marex Board and Marex’s continued growth. In some cases, these forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions.

These forward-looking statements are subject to risks, uncertainties and assumptions, some of which are beyond our control. In addition, these forward-looking statements reflect our current views with respect to future events and are not a guarantee of future performance. Actual outcomes may differ materially from the information contained in the forward-looking statements as a result of a number of factors, including, without limitation, the risks discussed under the caption “Risk Factors” in our Annual Report on Form 20-F for the year ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) and our other reports filed with the SEC. The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.

About Marex: Marex Group Limited (NASDAQ:MRX) provides market access, infrastructure services and essential liquidity to clients across global commodity and financial markets. The Group provides comprehensive breadth and depth of coverage across four services: Clearing, Agency and Execution, Market Making and Hedging and Investment Solutions. It has a leading franchise in many major metals, energy and agricultural products, with access to more than 60 exchanges. Marex has over 3,400 active clients, including some of the largest commodity producers, consumers and traders, banks, hedge funds and asset managers. With more than 50 offices worldwide, the Group has over 3000 employees across Europe, Asia and the Americas. For more information visit www.marex.com.

Enquiries please contact:

Nicola Ratchford / Adam Strachan

+44 778 654 8889 / +1 914 200 2508

nratchford@marex.com / astrachan@marex.com

FTI Consulting US / UK

+1 716 525 7239 / +44 7976870961

marex@fticonsulting.com

JERSEY, Channel Islands, 27th October 2026 – CoinShares PLC (Nasdaq: CSHR) (“CoinShares” or the “Company”) today announced that its Board of Directors has approved a program to repurchase up to $40 million of the Company’s ordinary shares, pursuant to the shareholder authority granted at the 15th of September 2026 Extraordinary General Meeting. The program will remain authorised until the Company’s next Annual General Meeting, expected in Q2 2027.

The program will be funded from existing digital asset treasury resources. In preparation, CoinShares sold its corporate treasury holding of Ethereum (16.6 million) and 50% of its corporate treasury holding of Solana (2.7 million) earlier this month, reallocating that capital towards share repurchases.

The Board believes that, given current valuation levels, with the Company’s 26Q3 AUM in line with 25Q4 level, repurchasing CoinShares shares represents a more attractive use of this capital than retaining the corresponding digital asset holdings. The program reflects confidence in the Company’s earnings potential and is intended to enhance long-term shareholder value, while preserving sufficient liquidity to fund operations and pursue its growth strategy.

Repurchases will be conducted in the open market, considering applicable blackout periods, via independent brokers, in accordance with applicable law and the conditions of the SEC’s Rule 10b-18 safe harbor, and may be effected through trading plans established under Rule 10b5-1.

The timing and amount of repurchases will depend on market conditions and other relevant factors. The program does not oblige the Company to repurchase any minimum amount and may be suspended or discontinued at any time.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding potential share repurchase, capital allocation, market conditions, future growth opportunities, and CoinShares’ business and strategy; and other statements identified by words such as “believes,” “expects,” “may,” and “will”. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Additional risk factors are described in the Company’s Annual Report on Form 20-F for the fiscal year ended December 31, 2025, and other filings and submissions with the U.S. Securities and Exchange Commission. CoinShares does not undertake any obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.

About CoinShares

CoinShares PLC (“CoinShares”) is a leading global asset manager specialising in digital assets, that delivers a broad range of financial services across investment management, trading and securities to a wide array of clients that includes corporations, financial institutions and individuals. Focusing on crypto since 2013, the firm is headquartered in Jersey, with offices in France, Sweden, Switzerland, the UK and the United States. CoinShares’ affiliated entities are regulated in Jersey by the Jersey Financial Services Commission, in France by the Autorité des marchés financiers, and in the US by the Securities and Exchange Commission, National Futures Association and Financial Industry Regulatory Authority. CoinShares PLC is publicly listed on the Nasdaq under the ticker CSHR.

Investor Relations Contact: corporateir@coinshares.com
Investor Relations Website: https://investor.coinshares.com

The Company Makes Significant Strategic Investments While Improving Underlying Financial Performance and Generating Record Quarterly Free Cash Flow of $20 Million

EDMONTON, Alberta, Oct. 27, 2026 (GLOBE NEWSWIRE) — SNDL Inc. (NASDAQ/CSE: SNDL) (“SNDL” or the “Company”) reported its financial and operational results for the third quarter ended September 30, 2026. All financial information in this press release is reported in millions of Canadian dollars unless otherwise indicated.

SNDL has also posted a supplemental investor presentation on its website, found at https://sndl.com.

The Company will hold a conference call and webcast presentation at 10:00 a.m. EDT (8:00 a.m. MDT) on Tuesday, October 27, 2026. The conference call details can be found below.

MANAGEMENT HIGHLIGHTS

• Net revenue for the third quarter of 2026 was $238.0 million, representing a -2.5% decrease compared with the same period of the prior year. Cannabis Retail revenue increased by 0.7%, while Liquor Retail and Cannabis Operations revenue declined by -3.3% and -27.7%, respectively.
• Gross profit of $57.9 million for the third quarter of 2026 represents a decline of $(6.3) million, or -9.8%, compared with the same period of the prior year.
• Gross margin ⁽¹⁾ was 24.3% in the third quarter of 2026, a decrease of 2.0 percentage points compared with the same period of the prior year, primarily reflecting weak performance of Cannabis Operations. Both retail segments delivered strong margin expansion and reached new quarterly records.
• Operating loss was $(48.3) million for the third quarter of 2026, reflecting a $52 million non-cash goodwill impairment charge related to the Cannabis Operations segment.
• Adj. operating income ⁽¹⁾, which excludes impairment charges and restructuring costs, returned to positive territory at $5.2 million, an improvement of $14.8 million compared with the same period of the prior year.
• Cash flow was $(50.7) million, reflecting $60.8 million of strategic investments in the U.S. and $10.0 million of additional share repurchases, consistent with our capital allocation priorities.
• Free cash flow ⁽¹⁾ reached a new quarterly record of $20.0 million in the third quarter of 2026, an increase of $3.3 million, or 19.5%, compared with the same period of the prior year, including a $10.6 million benefit associated with the initial unwinding of the Company’s captive insurance arrangement.

“Our third quarter results demonstrate improvement in SNDL’s underlying financial performance, including positive adjusted operating income and record quarterly free cash flow generation,” said Zach George, Chief Executive Officer of SNDL. “Cannabis Retail delivered record quarterly revenue and gross margin, Liquor Retail also reached a new record quarterly gross margin, and our Investments segment benefited from improved results from equity-accounted investees.”

“Cannabis Operations remained below expectations and recorded a non-cash impairment. While the quarter was impacted by inventory issues arising from the first half, we are taking decisive action to simplify the portfolio, reduce costs and concentrate resources on product categories where SNDL’s manufacturing capabilities, distribution reach and retail insights can support sustainable returns. The benefits of the actions taken during the quarter are expected to begin contributing to results in the fourth quarter. In addition to these immediate actions, the Company is initiating a strategic review of the Cannabis Operations segment to assess opportunities to improve its financial performance. The review will consider a range of strategic and operational alternatives, from potential asset divestitures to larger productivity initiatives.”

“The completion of the restructuring of Surterra Holdings, Inc. (“Parallel”) in July of this year, which reduced its debt burden by approximately US$842 million, and the subsequent rights offering, which increased our indirect equity ownership from approximately 67% to 92%, represent important steps in resetting Parallel’s capital structure and providing liquidity to support inventory, product availability and critical supply-chain infrastructure. SNDL-funded investments by SunStream Bancorp Inc. (“SunStream”) in a new cultivation facility in Gainesville, Florida, are expected to enhance Parallel’s cost structure. We are excited by the opportunity presented by our investment in Parallel and are actively exploring the feasibility of transitioning our indirect economic exposure to direct ownership and consolidation of qualifying U.S. medical cannabis operations, subject to applicable legal, regulatory, accounting and Nasdaq requirements.”

“We are encouraged by the progress made toward resolving the regulatory matters involving the Alcohol and Gaming Commission of Ontario (“AGCO”), which we expect will provide greater clarity for the Ontario franchise retail operations and future development opportunities, as further detailed later in this document and in the Q3 2026 Earnings Call presentation.”

“Across SNDL, our priorities remain disciplined capital allocation, improved operating performance and long-term value creation for shareholders. We have demonstrated that commitment through significant share repurchases, and we intend to remain aggressive when we believe the opportunity to acquire our shares represents an attractive use of capital. The recently announced potential $50 million substantial issuer bid (“SIB”) is a further step toward accelerating capital returns and reducing our outstanding share count,” concluded Zach George.

TOTAL COMPANY HIGHLIGHTS

	Three months ended September 30									Nine months ended September 30
($000s)	2026			2025			% Change			2026			2025			% Change
IFRS Financial Measures
Net revenue		237,994			244,219			-2.5	%		669,666			693,902			-3.5	%
Gross profit		57,886			64,177			-9.8	%		167,047			188,419			-11.3	%
Operating income (loss)		(48,317	)		(11,050	)		-337.3	%		(65,272	)		(18,100	)		-260.6	%
Change in cash and cash equivalents		(50,729	)		32,357			-256.8	%		(107,622	)		22,222			-584.3	%
Non-IFRS Financial Measures (1)
Gross margin		24.3	%		26.3	%		-2.0	pp		24.9	%		27.2	%		-2.2	pp
Adjusted operating income (loss)		5,249			(9,512	)		155.2	%		(10,675	)		(12,713	)		16.0	%
Free cash flow		19,954			16,692			19.5	%		5,692			7,733			-26.4	%

(1)   Gross Margin is a supplementary financial measure calculated by dividing Gross Profit by Net Revenue. Adjusted operating income (loss) and Free Cash Flow are specified financial measures that do not have standardized meanings under IFRS and therefore may not be comparable to similar measures reported by other companies. See “Non-IFRS Measures” section below for further information.

BUSINESS SEGMENT HIGHLIGHTS

SNDL operates and reports its business through four segments: Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments. Additionally, a consolidated total for Cannabis is presented, encompassing the combined results of the two Cannabis segments, along with the revenue elimination associated with the Cannabis Operations sales to the provincial boards that are expected to be subsequently repurchased by the Company’s licensed retail subsidiaries for resale. Corporate and shared service expenses are reported as “Corporate”.

	Three months ended September 30									Nine months ended September 30
($000s)	2026			2025(2)			% Change			2026			2025(2)			% Change
Net Revenue
Cannabis Retail		85,605			85,021			0.7	%		246,154			246,960			-0.3	%
Cannabis Operations		27,040			37,389			-27.7	%		88,704			107,544			-17.5	%
Intersegment Eliminations		(9,425	)		(17,579	)		46.4	%		(38,757	)		(51,391	)		24.6	%
Total Cannabis		103,220			104,831			-1.5	%		296,101			303,113			-2.3	%
Liquor Retail		134,774			139,388			-3.3	%		373,565			390,789			-4.4	%
Investments		—			—			0.0	%		—			—			0.0	%
Total		237,994			244,219			-2.5	%		669,666			693,902			-3.5	%
Operating Income
Cannabis Retail		5,244			5,047			3.9	%		9,328			10,557			-11.6	%
Cannabis Operations		(64,693	)		(10,882	)		-494.5	%		(80,836	)		(20,186	)		-300.5	%
Total Cannabis		(59,449	)		(5,835	)		-918.8	%		(71,508	)		(9,629	)		-642.6	%
Liquor Retail		6,035			6,591			-8.4	%		5,899			10,884			-45.8	%
Investments		7,861			1,543			409.5	%		8,340			1,775			369.9	%
Corporate		(2,764	)		(13,349	)		79.3	%		(8,003	)		(21,130	)		62.1	%
Total		(48,317	)		(11,050	)		-337.3	%		(65,272	)		(18,100	)		-260.6	%
Adjusted Operating Income
Cannabis Retail		5,284			5,047			4.7	%		9,403			10,557			-10.9	%
Cannabis Operations		(11,391	)		(10,220	)		-11.5	%		(27,303	)		(16,258	)		-67.9	%
Total Cannabis		(6,107	)		(5,173	)		-18.1	%		(17,900	)		(5,701	)		-214.0	%
Liquor Retail		6,037			6,591			-8.4	%		6,126			10,884			-43.7	%
Investments		7,861			1,543			409.5	%		8,340			1,775			369.9	%
Corporate		(2,542	)		(12,473	)		79.6	%		(7,241	)		(19,671	)		63.2	%
Total		5,249			(9,512	)		155.2	%		(10,675	)		(12,713	)		16.0	%

(2)   In 2026, the Company began allocating applicable direct and indirect overhead costs from the corporate segment to each individual operating segment all categorized within general and administrative expenses. The Company has recast the comparative period to illustrate the impact of these allocations had they been done during the prior period, as documented in the condensed interim Financial Statements.

Liquor Retail 

SNDL is Canada’s largest private-sector liquor retailer, operating as of October 26, 2026 in 165 locations, predominantly in Alberta, under its three retail banners: “Wine and Beyond” (16), “Liquor Depot” (19), and “Ace Liquor” (130).

	Three months ended September 30									Nine months ended September 30
($000s)	2026			2025			% Change			2026			2025			% Change
Net revenue		134,774			139,388			-3.3	%		373,565			390,789			-4.4	%
Gross profit		36,390			36,704			-0.9	%		96,828			100,993			-4.1	%
Gross margin		27.0	%		26.3	%		0.7	pp		25.9	%		25.8	%		0.1	pp
Operating income		6,035			6,591			-8.4	%		5,899			10,884			-45.8	%
Adjusted operating income		6,037			6,591			-8.4	%		6,126			10,884			-43.7	%

• Net revenue for Liquor Retail continued to decline year over year in the third quarter of 2026, although at a slightly better rate than in previous quarters. Persistent softness in market demand continued to affect same-store sales⁽³⁾, which decreased by -6.0% compared with the same period in the prior year.
• Operating income declined year over year, driven by lower revenue, increased promotional support, and higher SG&A expenses associated with the recent Wine & Beyond store openings, partly offset by strong gross margin expansion, which reached a new quarterly record.

(3)   Same-store sales is a specified financial measure that does not have standardized meanings under IFRS and therefore may not be comparable to similar measures used by other companies. See “Non-IFRS Measures” section below for further information.

Cannabis Retail

SNDL is one of Canada’s largest private-sector cannabis retailers, operating as of October 26, 2026 in 193 locations under two retail banners: “Value Buds” (133) and “Spiritleaf” (60, of which 4 are corporate stores and 56 are franchise stores). The Company’s Cannabis Retail strategy is based on several pillars, including high-quality store locations, a broad product assortment and differentiated customer experiences. Using data and insights from a large volume of monthly transactions enables SNDL to leverage technology and analytics to inform and improve its retail strategy.

	Three months ended September 30									Nine months ended September 30
($000s)	2026			2025			% Change			2026			2025			% Change
Net revenue		85,605			85,021			0.7	%		246,154			246,960			-0.3	%
Gross profit		23,118			22,465			2.9	%		65,472			63,974			2.3	%
Gross margin		27.0	%		26.4	%		0.6	pp		26.6	%		25.9	%		0.7	pp
Operating income		5,244			5,047			3.9	%		9,328			10,557			-11.6	%
Adjusted operating income		5,284			5,047			4.7	%		9,403			10,557			-10.9	%

• Net revenue for Cannabis Retail returned to growth in the third quarter compared with the same period of the prior year, consistent with the previously anticipated inflection point, and reached a new quarterly record. Market contraction in our largest provinces (ON, AB) contributed to a -3.8% decline in same-store sales. This decline was partially offset by incremental revenue from new stores and Value Buds store conversions.
• Operating income increased compared with the same period of the prior year, primarily driven by gross margin expansion, which reached a new quarterly record, despite lapping a larger impairment reversal recorded in the third quarter of 2025.
• Subject to completion of definitive documentation and payment of a $200,000 monetary penalty, the anticipated resolution of the regulatory matters involving the AGCO is expected to allow the Value Buds franchise network to resume growth in Ontario following a pause of more than a year during the regulatory review. While the contemplated structure is expected to result in the deconsolidation of the Ontario retail operations from SNDL’s financial statements, we expect the overall commercial arrangements to substantially preserve SNDL’s net economics associated with these franchise locations, without retaining control over the retail operations in the province.

Cannabis Operations

SNDL has a diverse brand portfolio from value to premium, emphasizing premium inhalable formats and a full suite of 2.0 products. With enhanced procurement capabilities and plans to continue evolving toward a cost-effective cultivation and manufacturing operation, the Cannabis Operations segment is a key enabler of SNDL’s vertical integration strategy.

	Three months ended September 30									Nine months ended September 30
($000s)	2026			2025			% Change			2026			2025			% Change
Net revenue		27,040			37,389			-27.7	%		88,704			107,544			-17.5	%
Gross profit		(1,622	)		5,008			-132.4	%		4,747			23,452			-79.8	%
Gross margin		-6.0	%		13.4	%		-19.4	pp		5.4	%		21.8	%		-16.5	pp
Operating income (loss)		(64,693	)		(10,882	)		-494.5	%		(80,836	)		(20,186	)		-300.5	%
Adjusted operating income (loss)		(11,391	)		(10,220	)		-11.5	%		(27,303	)		(16,258	)		-67.9	%

• Our Cannabis Operations results remain below our expectations, and we are moving aggressively to reshape the segment into a more focused and efficient business. Most of the revenue decline in the third quarter was attributable to our exit from the unprofitable domestic dried flower category and our increased focus on higher-value products.
• Profitability was impacted by a $52 million non-cash goodwill impairment reflecting current business trends, as well as $6 million in other impacts, mostly driven by inventory adjustments related to the exit from the dried flower category and Jeeter cost variances. During the third quarter, we took decisive actions to reduce manufacturing costs and other operating expenses, particularly at our Kelowna manufacturing facility, including a reduction of more than 30% of the workforce at the site. The P&L benefits of these cost reductions are expected to begin contributing to results in the fourth quarter.

Investments

• As of September 30, 2026, the Company’s portfolio of cannabis-related investments had a carrying value of $485.2 million, including $467.7 million to SunStream Bancorp Inc. (“SunStream”). This carrying value was increased by $70.0 million during the third quarter of 2026, primarily driven by additional contributions to fund the buildout of the Gainesville, Florida cultivation facility, SNDL’s participation in Parallel’s rights offering, and the purchase of an incremental portion of Parallel’s debt.
• On July 27, 2026, the restructuring of Parallel was completed, providing SNDL with indirect majority economic exposure to the company. During the third quarter, SNDL participated in a Parallel rights offering, while other minority holders declined to participate, increasing SNDL’s indirect equity interest from approximately 67% to approximately 92%. SNDL continues to evaluate a pathway to directly own and consolidate Parallel’s U.S. medical cannabis operations while maintaining compliance with the applicable Nasdaq requirements. Consistent with recent public-market precedents, SNDL is evaluating structures that distinguish medical cannabis operations from adult-use exposure, with the latter expected to remain outside SNDL’s consolidated operations. The Company is actively advancing this work and expects to provide further clarity as the structure and timing are finalized, subject to applicable legal, regulatory, accounting and Nasdaq requirements.
• Following the completion of Parallel’s restructuring, SNDL also financed SunStream’s purchase of an additional portion of Parallel’s takeback debt at 75% of face value, increasing SunStream’s debt ownership from 39.4% to 69.4%.
• The Investments segment generated $7.9 million of operating income during the third quarter of 2026, including $6.9 million from SNDL’s share of profit from SunStream’s equity-accounted investees, primarily reflecting an increase in the valuation of Parallel.
• The previously disclosed restructuring process relating to Skymint continues. On April 1, 2026, the Michigan Supreme Court agreed to hear oral argument on applications for leave to appeal. The Court has not reached a decision on the merits. Timing and outcomes remain uncertain and are subject to court process and other factors.
• On April 23, 2026, the United States Department of Justice and the United States Drug Enforcement Administration issued an order placing Food and Drug Administration-approved cannabis products and qualifying state-regulated medical cannabis in Schedule III of the United States Controlled Substances Act, while initiating an expedited administrative process to consider the broader rescheduling of cannabis, including adult-use cannabis, from Schedule I to Schedule III. The administrative hearing concluded in July 2026, with a final determination on broader rescheduling still pending.

Equity Position

• $617.8 million of unrestricted cash, marketable securities and investments, including investments in equity-accounted investees, and no outstanding debt at September 30, 2026, resulting in a net book value of $1.0 billion.
• During the third quarter of 2026, the Company purchased for cancellation 5,431,300 common shares at a weighted average price, excluding commissions, of US$1.31 per share. Year-to-date through October 22, 2026, the Company had purchased for cancellation 23,088,153 common shares, resulting in 243,320,644 common shares outstanding.
• As recently communicated, the Company’s Board of Directors has directed management to pursue a possible substantial issuer bid (“SIB”) for an aggregate purchase price of up to C$50 million and at a price per share not exceeding C$1.92 (US$1.35). If completed and fully subscribed at the maximum price, the SIB could reduce the Company’s common shares outstanding by more than an additional 10%. SNDL will continue to evaluate opportunities to repurchase shares where management believes doing so is in the best interests of SNDL and its shareholders. In this context, and subject to approval by SNDL’s Board of Directors, we expect to proceed with the renewal of the share repurchase program upon its expiration on November 20, 2026, supported by continued free cash flow and potential targeted asset sales, including non-core real estate and other operating assets.

This press release is intended to be read in conjunction with the Company’s condensed consolidated interim financial statements and the notes thereto for the three and nine months ended September 30, 2026, and the accompanying Management’s Discussion and Analysis. These documents are available under the Company’s profile on SEDAR+ at www.sedarplus.ca and EDGAR at www.sec.gov/edgar.shtml. 

CONFERENCE CALL  

The Company will hold a conference call and webcast presentation at 10:00 a.m. EDT (8:00 a.m. MDT) on Tuesday, October 27, 2026.

WEBCAST ACCESS
To access the live webcast of the call, please visit the following link:
https://edge.media-server.com/mmc/p/wcotys5n

REPLAY

A replay of the webcast will be available at https://sndl.com/financials/quarterly-results/default.aspx

ABOUT SNDL INC. 

SNDL Inc. (NASDAQ: SNDL, CSE: SNDL), through its wholly owned subsidiaries, is one of the largest vertically integrated cannabis companies and the largest private-sector liquor and cannabis retailer in Canada, with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, and Spiritleaf. With products available in licensed cannabis retail locations nationally, SNDL’s consumer-facing cannabis brands include Top Leaf, Contraband, Palmetto, Bon Jak, La Plogue, Versus, Value Buds, Grasslands, Vacay, Pearls by Grön, No Future and Bhang Chocolate. SNDL’s investment portfolio seeks to deploy strategic capital through direct and indirect investments and partnerships throughout the North American cannabis industry. For more information, please visit www.sndl.com 

For more information: 
Tomas Bottger
Investor Relations, SNDL Inc. 
O: 1.587.327.2017 
E: investors@sndl.com

Forward-Looking Information Cautionary Statement    
This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”), including, but not limited to, statements regarding the Company’s operational goals, plans and key priorities, the strategic review of the Cannabis Operations segment, including its scope, potential alternatives and outcomes, and the expected benefits of any actions resulting from the review, the Company’s ability to deploy capital and the expected benefits thereof, expectations related to the Jeeter contract, the growth opportunities available to SNDL and the expected benefits thereof, expectations with respect to the 1CM transaction, including the satisfaction of certain regulatory approvals, the progress of the Sunstream restructurings, expectations with respect to the Skymint and Parallel restructuring processes, the feasibility, structure, timing and expectations related to the Company obtaining direct ownership and control of, and consolidating, qualifying U.S. medical cannabis operations of Parallel, SNDL’s corporate restructuring program, including the timing to conclude the restructuring and expected benefits thereof, the expected benefits of the enterprise resource planning (“ERP”) system consolidation, SNDL’s ability to recover the senior secured notes held in Cannabist, the timing and expected impact of reclassifying cannabis from Schedule I to Schedule III under the United States Controlled Substances Act, the Company’s retail strategy, and any other potential forms of shareholder value creation. Forward-looking statements are frequently characterized by words such as “aim”, “anticipate”, “assume”, “believe”, “contemplate”, “continue”, “could”, “due”, “estimate”, “expect”, “goal”, “intend”, “may”, “objective”, “plan”, “predict”, “potential”, “positioned”, “pioneer”, “seek”, “should”, “target”, “will”, “would”, and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the Company’s business and the industry in which it operates and management’s beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond its control. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Please see “Risk Factors” in the Company’s annual information form dated March 11, 2026, and the risk factors included in our other public disclosure documents for a discussion of the material risk factors that could cause actual results to differ materially from the forward-looking information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law. 

Condensed Consolidated Interim Statement of Loss and Comprehensive Loss
(Expressed in thousands of Canadian dollars, except per share amounts)
		Three months ended September 30								Nine months ended September 30
		2026				2025				2026				2025
Net revenue			237,994				244,219				669,666				693,902
Cost of sales			180,108				180,042				502,619				505,483
Gross profit			57,886				64,177				167,047				188,419
Investment income			927				1,777				3,472				6,162
Share of profit (loss) of equity-accounted investees			6,934				(234	)			5,084				(4,387	)
General and administrative			43,284				45,967				132,732				137,702
Sales and marketing			3,462				3,617				11,136				10,768
Depreciation and amortization			12,659				12,928				38,145				39,076
Share-based compensation			1,767				10,883				5,033				15,190
Restructuring costs			577				1,134				1,608				2,287
Asset impairment, net			52,331				2,051				52,151				2,971
Other income			—				—				(81	)			—
Research and development			—				156				12				354
(Gain) loss on disposition of assets			(16	)			34				139				(54	)
Operating loss			(48,317	)			(11,050	)			(65,272	)			(18,100	)
Other expenses, net			(2,464	)			(2,269	)			(6,424	)			(7,041	)
Loss before income tax			(50,781	)			(13,319	)			(71,696	)			(25,141	)
Income tax (expense) recovery			(8	)			—				3,174				—
Net loss			(50,789	)			(13,319	)			(68,522	)			(25,141	)
Equity-accounted investees – share of other comprehensive (loss) income			(29	)			7,709				10,625				(13,250	)
Investments at fair value through other comprehensive income (“FVOCI”) – change in fair value			2,773				12,940				1,690				9,754
Comprehensive (loss) income			(48,045	)			7,330				(56,207	)			(28,637	)

Condensed Consolidated Interim Statement of Financial Position
(Expressed in thousands of Canadian dollars)
As at	September 30, 2026			December 31, 2025
Assets
Current assets
Cash and cash equivalents		132,479			252,243
Restricted cash		8,162			20,081
Marketable securities		139			84
Accounts receivable		31,734			27,643
Biological assets		2,407			3,120
Inventory		128,721			126,877
Prepaid expenses and deposits		16,614			15,566
Investments		106			484
Assets held for sale		700			746
Net investment in subleases		2,997			2,775
		324,059			449,619
Non-current assets
Long-term deposits and receivables		2,457			4,526
Right of use assets		131,608			138,353
Property, plant and equipment		139,376			151,900
Net investment in subleases		9,954			11,643
Intangible assets		56,434			58,520
Investments		17,314			11,574
Equity-accounted investees		467,730			385,534
Goodwill		75,238			124,248
Total assets		1,224,170			1,335,917
Liabilities
Current liabilities
Accounts payable and accrued liabilities		46,902			56,747
Lease liabilities		35,706			35,462
		82,608			92,209
Non-current liabilities
Lease liabilities		126,614			134,471
Other liabilities		7,753			8,041
Total liabilities		216,975			234,721
Shareholders’ equity
Share capital		2,127,355			2,310,398
Warrants		306			306
Contributed surplus		53,377			54,038
Accumulated deficit		(1,225,053	)		(1,302,441	)
Accumulated other comprehensive income (“AOCI”)		51,210			38,895
Total shareholders’ equity		1,007,195			1,101,196
Total liabilities and shareholders’ equity		1,224,170			1,335,917

Condensed Consolidated Interim Statement of Cash Flows
(Expressed in thousands of Canadian dollars)
		Three months ended September 30								Nine months ended September 30
		2026				2025				2026				2025
Cash provided by (used in):
Operating activities
Net loss for the period			(50,789	)			(13,319	)			(68,522	)			(25,141	)
Adjustments for:
Income tax expense (recovery)			8				—				(3,174	)			—
Interest and fee income			(927	)			(1,675	)			(3,417	)			(5,849	)
Change in fair value of biological assets			585				180				594				(2,559	)
Change in fair value of inventory sold			(276	)			349				249				1,313
Share-based compensation			1,767				10,883				5,033				15,190
Depreciation and amortization			13,893				13,972				41,998				42,108
(Gain) loss on disposition of assets			(16	)			34				139				(54	)
Inventory impairment and obsolescence			3,455				1,833				6,057				2,663
Finance costs, net			1,951				1,812				6,007				5,149
Change in estimate of fair value of derivative warrants			—				(1	)			—				(26	)
Unrealized foreign exchange loss (gain)			180				(153	)			(832	)			40
Transaction costs			—				—				10				—
Asset impairment, net			52,331				2,051				52,151				2,971
Share of (profit) loss of equity-accounted investees			(6,934	)			234				(5,084	)			4,387
Unrealized (gain) on marketable securities			—				(102	)			(55	)			(313	)
Additions to marketable securities			—				—				151				313
Income distributions from equity-accounted investees			315				—				315				68
Interest received			822				1,409				3,377				5,628
Exercise of cash-settled deferred share units			—				—				(474	)			—
Change in non-cash working capital			2,185				14,194				(8,805	)			(282	)
Net cash provided by operating activities			18,550				31,701				25,718				45,606
Investing activities
Additions to property, plant and equipment			(1,196	)			(5,185	)			(5,620	)			(8,853	)
Additions to investments			—				—				(4,183	)			(16,414	)
Principal payments from investments			121				129				359				27,293
Proceeds from disposal of investments			—				15,058				—				15,058
Capital (contributions) distributions from equity-accounted investees			(60,762	)			481				(63,628	)			4,273
Proceeds from disposal of property, plant and equipment			538				—				2,332				166
Acquisitions			—				—				(2,900	)			(1,000	)
Change in non-cash working capital			75				39				712				10
Net cash (used in) provided by investing activities			(61,224	)			10,522				(72,928	)			20,533
Financing activities
Change in restricted cash			11,950				—				11,950				—
Payments on lease liabilities, net			(10,228	)			(9,920	)			(30,385	)			(29,217	)
Repurchase of common shares			(10,042	)			(3	)			(43,113	)			(15,034	)
Change in non-cash working capital			265				57				1,136				334
Net cash used in financing activities			(8,055	)			(9,866	)			(60,412	)			(43,917	)
Change in cash and cash equivalents			(50,729	)			32,357				(107,622	)			22,222
Adjustment on initial application of amendments to IFRS 9 on January 1, 2026			—				—				(12,142	)			—
Cash and cash equivalents, beginning of period			183,208				208,224				252,243				218,359
Cash and cash equivalents, end of period			132,479				240,581				132,479				240,581

NON-IFRS MEASURES

Certain specified financial measures in this news release are non-IFRS measures. These terms are not defined by IFRS and, therefore, may not be comparable to similar measures reported by other companies. These non-IFRS financial measures should not be considered in isolation or as an alternative for or superior to measures of performance prepared in accordance with IFRS. These measures are presented and described in order to provide shareholders and potential investors with additional measures in understanding the Company’s operating results in the same manner as the management team.  

ADJUSTED OPERATING INCOME (LOSS)
Adjusted operating income (loss) is a non-IFRS financial measure which the Company uses to evaluate its operating performance in a similar manner to its management team. The Company defines adjusted operating income (loss) as operating income (loss) less restructuring costs (recovery), goodwill and intangible asset impairments and asset impairments triggered by restructuring activities.

The following tables reconcile adjusted to un-adjusted operating income (loss) for the periods noted.

($000s)	Cannabis Retail			Cannabis Operations			Cannabis Total			Liquor Retail			Investments			Corporate			Total
Three months ended September 30, 2026
Operating income (loss)		5,244			(64,693	)		(59,449	)		6,035			7,861			(2,764	)		(48,317	)
Adjustments:
Restructuring costs		40			313			353			2			—			222			577
Goodwill and intangible asset impairments		—			52,022			52,022			—			—			—			52,022
Impairments triggered by restructuring		—			967			967			—			—			—			967
Adjusted operating income (loss)		5,284			(11,391	)		(6,107	)		6,037			7,861			(2,542	)		5,249

($000s)	Cannabis Retail			Cannabis Operations			Cannabis Total			Liquor Retail			Investments			Corporate			Total
Nine months ended September 30, 2026
Operating income (loss)		9,328			(80,836	)		(71,508	)		5,899			8,340			(8,003	)		(65,272	)
Adjustments:
Restructuring costs		75			544			619			227			—			762			1,608
Goodwill and intangible asset impairments		—			52,022			52,022			—			—			—			52,022
Impairments triggered by restructuring		—			967			967			—			—			—			967
Adjusted operating income (loss)		9,403			(27,303	)		(17,900	)		6,126			8,340			(7,241	)		(10,675	)

($000s)	Cannabis Retail			Cannabis Operations			Cannabis Total			Liquor Retail			Investments			Corporate			Total
Three months ended September 30, 2025
Operating income (loss)(1)		5,047			(10,882	)		(5,835	)		6,591			1,543			(13,349	)		(11,050	)
Adjustments:
Restructuring costs		—			258			258			—			—			876			1,134
Impairments triggered by restructuring		—			404			404			—			—			—			404
Adjusted operating income (loss)		5,047			(10,220	)		(5,173	)		6,591			1,543			(12,473	)		(9,512	)
($000s)	Cannabis Retail			Cannabis Operations			Cannabis Total			Liquor Retail			Investments			Corporate			Total
Nine months ended September 30, 2025
Operating income (loss)(1)		10,557			(20,186	)		(9,629	)		10,884			1,775			(21,130	)		(18,100	)
Adjustments:
Restructuring costs		—			828			828			—			—			1,459			2,287
Impairments triggered by restructuring		—			3,100			3,100			—			—			—			3,100
Adjusted operating income (loss)		10,557			(16,258	)		(5,701	)		10,884			1,775			(19,671	)		(12,713	)

(4)   In 2026, the Company began allocating applicable direct and indirect overhead costs from the corporate segment to each individual operating segment all categorized within general and administrative expenses. The Company has recast the comparative period to illustrate the impact of these allocations had they been done during the prior period.

GROSS MARGIN
Gross margin is a supplementary financial measure calculated as gross profit divided by net revenue for the periods presented. This measure evaluates the underlying profitability of our operations and provides useful information about the Company’s ability to price products effectively, manage input costs, drive operating efficiencies, and compare results across periods and business segments

FREE CASH FLOW
Free cash flow is a non-IFRS financial measure which the Company uses to evaluate its financial performance, providing information which management believes to be useful in understanding and evaluating the Company’s ability to generate positive cash flows as it removes cash used for non-operational items. The Company defines free cash flow as the total change in cash and cash equivalents less cash used for common share repurchases, dividends (if any), changes to debt instruments, changes to long-term investments, net cash used for acquisitions plus cash provided by dispositions (if any).

The following table reconciles free cash flow to change in cash and cash equivalents for the periods noted.

		Three months ended September 30								Nine months ended September 30
($000s)		2026				2025				2026				2025
Change in cash and cash equivalents			(50,729	)			32,357				(107,622	)			22,222
Adjustments:
Repurchase of common shares			10,042				3				43,113				15,034
Changes to long-term investments			60,641				(15,668	)			67,301				(30,523	)
Acquisitions, net of cash acquired			—				—				2,900				1,000
Free cash flow			19,954				16,692				5,692				7,733

SAME-STORE SALES
Same-store sales is a non-IFRS financial measure which the Company uses to evaluate its financial performance in its retail segments. Same store sales provides information which management believes to be useful to investors, analysts and others in understanding and evaluating the Company’s sales trends excluding the effect of the opening and closure of stores.

Same store sales refers to the revenue generated by the Company’s existing retail locations during the current and prior comparison periods.

ADJUSTED EBITDA
Adjusted EBITDA is a non-IFRS financial measure which the Company uses to evaluate its operating performance. Adjusted EBITDA provides information to investors, analysts, and others to aid in understanding and evaluating the Company’s operating results. The Company defines adjusted EBITDA as net earnings (loss) before inventory and biological assets fair value and impairment adjustments, share of (gain) loss of equity-accounted investees, depreciation and amortization, share-based compensation expense, restructuring costs, asset impairment, gain or loss on disposal of property, other expenses, net, income tax expense (recovery) and excluding non-recurring items including ERP implementation costs and litigation settlements, net of recoveries.

		Three months ended September 30								Nine months ended September 30
($000s)		2026				2025				2026				2025
Net earnings (loss)			(50,789	)			(13,319	)			(68,522	)			(25,141	)
Adjustments:
Inventory and biological assets fair value and impairment adjustments			3,764				2,362				6,900				1,417
Share of loss (profit) of equity-accounted investees			(6,934	)			234				(5,084	)			4,387
Depreciation and amortization			12,659				12,928				38,145				39,076
Share-based compensation			1,767				10,883				5,033				15,190
Restructuring costs			577				1,134				1,608				2,287
Asset (reversal) impairment			52,331				2,051				52,151				2,971
Loss (gain) on disposition of PP&E			(16	)			34				139				(54	)
Other expenses, net			2,464				2,269				6,424				7,041
Income tax recovery			8				—				(3,174	)			—
Non-recurring items			(15	)			(501	)			549				(696	)
Adjusted EBITDA			15,816				18,075				34,169				46,478

ATLANTA, Oct. 27, 2026 (GLOBE NEWSWIRE) — Descartes Systems Group (Nasdaq:DSGX) (TSX:DSG), the global leader in uniting logistics-intensive businesses in commerce, announced that Herschel Parts, a global manufacturer and distributor of aftermarket agricultural replacement parts to businesses and consumers, is using the Descartes Pacejet™ multicarrier shipping solution integrated with its enterprise resource planning (ERP) system. Herschel is processing 98% of its shipments through one workflow spanning parcel and less-than-truckload (LTL) carriers. By consolidating shipping workflows and carrier rating, Herschel has eliminated approximately 10 hours per week of manual data entry, gained immediate shipment visibility and identified carrier options that can be 5% to 10% less expensive for individual shipments.

“We previously managed parcel, regional delivery and LTL shipping in separate systems and carrier portals, requiring employees to re-enter tracking numbers, freight costs, weights and other shipment details. Some information did not reach our legacy ERP system until an overnight update, delaying visibility for customer service,” said Lori Archibold, Enterprise Systems Manager at Herschel Parts. “On an accelerated timetable, we deployed a new ERP system integrated with Descartes Pacejet, eliminating extra work and lowering shipping costs. Tracking information and shipping documents now move automatically between the systems. Two members of our shipping team each used to spend about an hour each day re-entering shipping data; now, there is no manual entry, and our pickers and packers are amazed by how straightforward the process is. In addition, having all carrier rates in one place has been eye-opening. We can easily find less expensive options and choose the provider and shipping mode that fit us best. The visibility has been a tremendous asset in identifying cost savings.”

Approximately 70% of Herschel’s shipments move by LTL, with the balance shipped as parcel. The mix includes long, irregularly shaped agricultural parts such as seven- and nine-foot sickles, making shipment dimensions and accessorial charges important to mode and carrier selection. Descartes Pacejet enables the team to compare parcel and LTL options using current rates and shipment characteristics. In one example, Herschel identified an $85 LTL option for a shipment that would have cost approximately $200 by parcel.

Descartes Pacejet is an ERP-integrated, multimodal and multicarrier shipping solution that helps manufacturers, distributors and other shippers improve cost control, fulfillment efficiency and customer service by managing parcel, LTL, freight and third-party logistics services in one place. It supports rate shopping across carriers and modes by incorporating shipment dimensions, residential status and accessorial charges, including those for nonstandard items, into comparisons before shipments are tendered. The solution also automates packing, shipping, labeling, customer notifications and data exchange, making tracking information immediately available to customer service teams and notifying customers when orders ship.

“We’re pleased the Descartes solution is helping Herschel reduce administration, make more informed parcel-versus-LTL transportation decisions and give customer service immediate access to shipment information,” said Mikel Richardson, General Manager, Ecommerce at Descartes. “For manufacturers and distributors managing complex parcel and LTL operations, ERP-integrated shipping automation can improve cost control and delivery efficiency while providing the visibility needed to offer a better customer experience.”

Learn more about Descartes Pacejet and Descartes’ Ecommerce Operations solutions.

About Herschel Parts

Founded in 1887, Herschel Parts is a global manufacturer and distributor of aftermarket agricultural replacement parts. The company manufactures many of its own products and serves distributors, dealers and end-user farmers through B2B and B2C sales channels across the United States, Canada and other global markets. Learn more at www.herschelparts.com.

About Descartes

Descartes powers more responsive, efficient, secure and sustainable international and domestic supply chains by uniting logistics-intensive businesses on its Global Logistics Network (GLN). Shippers, carriers, and logistics service providers connect and collaborate on the GLN leveraging technology, data and AI to manage last mile deliveries, domestic and international shipments, transportation rating and payment, global trade research, customs compliance and a variety of regulatory processes. Learn more about Descartes at www.descartes.com and connect with us on LinkedIn and X.

Global Media Contact
Cara Strohack
Tel: 226-750-8050
cstrohack@descartes.com

Cautionary Statement Regarding Forward-Looking Statements

This release contains forward-looking information within the meaning of applicable securities laws (“forward-looking statements”) that relate to Descartes’ ecommerce operations solution offerings and the potential benefits derived therefrom; and other matters. Such forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance achievements or developments to differ materially from those expressed or implied by such forward-looking statements. These factors include, but are not limited to, the factors and assumptions discussed under “Certain Factors That May Affect Future Results” in documents filed with the Securities and Exchange Commission, the Ontario Securities Commission and other securities regulatory authorities in Canada including Descartes’ most recently filed annual and interim management’s discussion and analysis which are available under Descartes’ profile through the EDGAR website at http://www.sec.gov or through the SEDAR+ website at http://www.sedarplus.com/. If any such risks occur, they could, among other consequences, materially adversely affect our business, financial condition or results of operations. In that case, the trading price of our common shares could decline, perhaps materially. Readers are cautioned not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Forward-looking statements are provided for the purposes of providing information about management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. We do not undertake or accept any obligation publicly update or revise any forward-looking statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.

HOUSTON, Oct. 27, 2026 (GLOBE NEWSWIRE) — DNOW Inc. (NYSE:DNOW) has scheduled a conference call to discuss the results for the third quarter of 2026 on Thursday, November 5, 2026 at 8:00 am (US Central Time). Financial results for the third quarter ending September 30, 2026 are expected to be released that morning before the market opens.

The call will be broadcast through the Investor Relations link on DNOW’s website at ir.dnow.com on a listen-only basis. Listeners should log in prior to the start of the call to register for the webcast. A replay of the call will be available online for thirty days following the conference call. Participants may also join the conference call by dialing 1-888-660-6431 within North America or 1-929-203-2118 outside of North America, Access Code: 7372055, fifteen minutes prior to the scheduled start time and asking for the “DNOW Earnings Conference Call.”

DNOW is a premier energy and industrial solutions provider with a legacy of over 160 years as a leading distributor of pipe, valves, fittings (PVF), gas products, pumps and fabricated equipment. Headquartered in Houston, Texas, with approximately 5,050 employees and a global network of distribution and engineering locations; we provide a broad mix of quality products our customers require to build and maintain essential infrastructure across the upstream, gas utilities, downstream and industrial and midstream markets. We deliver a comprehensive range of value-added supply chain solutions and technical product expertise, supported by advanced digital offerings. Our products and resources enable our customers to run their operations more efficiently and effectively, helping them to meet and exceed their business goals.

Source: DNOW Inc.

Mark Johnson
Senior Vice President and Chief Financial Officer
(281) 823-4754